Ligand Pharmaceuticals Incorporated (LGND) : Fridays money flow points at investors jumping to buy the stock on the weakness of price. $8.44 million worth of transactions were on upticks, whereas, the downticks accounted for $7.79 million worth of transactions. The net money flow was a positive $0.65 million and the uptick to downtick ratio was 1.08. The net money flow into the stock was $0 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $0 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Ligand Pharmaceuticals Incorporated (LGND) was trading at $106.12, down $0.93 during day. The stock slid -0.86% over the previous days close. For the week, the stock recorded 2.48% over the previous weeks close.
The company Insiders own 14.7% of Ligand Pharmaceuticals Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -4.65% . During last six month period, the net percent change held by insiders has seen a change of -16.99%.
In a related news, The Securities and Exchange Commission has divulged that Foehr Matthew W, officer (President and COO) of Ligand Pharmaceuticals Inc, had unloaded 12,500 shares at an average price of $122.14 in a transaction dated on August 5, 2016. The total value of the transaction was worth $1,526,750.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): stock was range-bound between the intraday low of $105.88 and the intraday high of $108.25 after having opened at $107.33 on Fridays session. The stock finally closed in the red at $107.33, a loss of -0.79%. The stock remained in the red for the whole trading day. The total traded volume was 358,896 shares. The stock failed to cross $108.25 in Fridays trading. The stocks closing price on Thursday was $107.04.
Ligand Pharmaceuticals Incorporated (LGND) has been under a strong bear grip, hence the stock is down -13.76% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.03% in the past 1 week. The stock has risen by 2.55% in the past week indicating that the buyers are active at lower levels, but the stock is down -13.88% in the past 4 weeks.
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Companys technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.